CDIO
What one share of Cardio Diagnostics Holdings holds
In Vitro and In Vivo Diagnostic Substances
Medicine for all. We believe that incorporating Cardio’s solutions into routine practice in primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.
Cardio Diagnostics Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$2.76 |
| Capex (buildings and equipment) | $0.07 |
| Free cash flow | −$2.48 |
| Cash and investments | $0.00 |
| Book value | $2.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.02 | −$16.00 | — | −$15.09 | — | $26.00 |
| 2022 | $0.01 | −$45.29 | — | −$49.46 | — | — |
| 2023 | $0.04 | −$19.81 | $1.36 | −$14.78 | — | $4.32 |
| 2024 | $0.04 | −$9.35 | $0.24 | −$5.81 | — | $6.24 |
| 2025 | $0.01 | −$3.71 | $0.11 | −$3.38 | — | $3.82 |